1Hoffmann JA, Kafatos FC, Janeway CA, et al. Phylogeneticperspectives in innate immunity[J]. Science, 1999,284 (5418):1313-1318.
2Lindorfer MA,Hahn CS,Foley PL,et al. Heteropolymer-medi-ated clearance of immune complexes via erythrocyte CR1:mechanisms and applications [J]. Immunol Rev, 2001,183: 10-24.
3Zaltzman AB,Van den Berg CW,Muzykantov VR,et al. Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor [J].Biochem J, 1995,307 (Pt3) : 651-656.
4Gordon DL, Papazaharoudakis H,Sadlon TA,et al. Upregulation of human neutrophil CD59,a regulator of the membrane attack complex of complement, following cell activation [J]. Immunol Cell Riol, 1994, 72(3) : 222-229.
3Kim Y J, Borsing L, Varki NM, et al. P-selectin deficiency attenuates tumor growth and metastasis [J] . Proc Natl Acad Sci, 1998, 95:9325.
4Bhatt DL, Topoi EJ. Scientific and therapeutic advances in antiplatelet therapy[J] . Nat Rev Drug Discov, 2003,2(1):15-28.
5Bartaler L, Relation between therapy for hyperthyroidism and the course of Grave'ophthalmopathy (J). N Eng Med,1998, 338:73-77.
6Dietleimm M, Dederichs B, Weigand A, et al. Radioiodine therapy and thyroid-associated orbitopathy, rish factors and prerentive iffects of glucocorticoids (J). Exp Clin Endocrinol Diabetes, 1999, 107(15):190-194.
7Bartalena L, Pinchera A, Marcooce C, et al. Management of Graves' ophthalmopathy, reality and perspectives (J). Endor Rev, 2000, 21(2):168-199.
8Sokol RJ, Booker D J, Stamps R. Erythrocyte nutoantibodies,autoimmune haemolysis, and carcinoms (J). J Clin Pathol,1994, 47:340-348.
10Bamford KB,Fan X,crowe SE,et al.Lymphocytes in the human gastric mucosa during Helicobacter pylori infection have a T-helper cell I phenotype.Gastroenterology,1998,114:482～492.
